Viriom China Wins Award at 2018 Zhongguancun International Frontier Science and Technology Innovation Competition

Viriom China has been named the only foreign finalist of the 2018 Zhongguancun International Frontier Science and Technology Innovation Competition. The Zhongguancun government offered Viriom China advantageous terms for research and manufacturing activities. It also supports Viriom’s regulatory and financing activities in China.

Viriom to Report Results from Phase 1b Clinical Trial of Once Weekly Oral HIV Treatment

SAN DIEGO, Dec. 21, 2018 /PRNewswire/ -- Viriom, Inc. (San Diego, CA) announced today that it plans to report results from its Phase 1b clinical trial of once weekly dosing of oral elsulfavirine (Elida®, VM1500), a potent long acting nonnucleoside reverse transcriptase inhibitor (NNRTI) in HIV-uninfected volunteers in March 2019. This trial is designed to evaluate the safety and pharmacokinetics of elsulfavirine dosed once weekly for up to 8 weeks in up to 36 HIV-uninfected volunteers at a single clinical site in Moscow, Russia.